Recent data indicate that receptor for activated C kinase 1 (RACK1) is a putative prognostic marker and drug target in breast cancer (BC). High RACK1 expression is negatively associated with overall survival, as it seems to promote BC progression. In tum
Becker, B. de Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J.M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. ...
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM (2018) Pembr...
Le texte complet de cet article est disponible en PDF. Abbreviations : ARK5, EMT, ERK, FBS, FDA, ICI, MAPK, MEK, mTOR, MMP, NCBI, NSCLC, NSGA, ORR, PI3K, P/S, PTC, RET, TMB, WASP Chemical compounds studied in this article : PLM-101 (no PubChem CID), Dasatinib (PubChem...
Colorectal cancer (CRC) is considered to develop slowly via the progressive accumulation of genetic mutations (1,2). Genes that regulate cell growth and differentiation must be altered in cancerous cells in the process of tumorigenesis (3,4). Markers of CRC may provide the basis for decision-...
Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J et al (2014) The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles 3:24858 Article CAS Google Scholar Gould SJ, Raposo G (2013) As we wait: coping...
(LLBBAA))oonnaaµμTTAASSWWaakkooi3i300aauutoto aannaalylyzzeerrwiwthitmh icmroiflcruoifdliucidchicip cIhOi6p(WIOak6o (PWuraekCohePmuricealCInhdeumsitcraiels,IHndyougstor,ieJasp, aHn)yfoogroe,lecJatrpoaknin) etfiocr aenlaeclytrtoektrinanetsipcoartnaslysatey (tEraAnTsApo) r(tFia...
International Journal of Molecular Sciences Article Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/ Exons 2–8) in Normal and Cancerous Breast and Prostate Cells Dong Gui Hu *, Ross A. McKinnon, Julie-Ann Hulin, Peter I. Mackenzie and Robyn Meech Department of Clinical Pharmacology and ...
Van Maerken, T.; Rihani, A.; Van Goethem, A.; De Paepe, A.; Speleman, F.; Vandesompele, J. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett. 2013, 344, 157–165. [CrossRef] [PubMed] 54. Brown, C.J.; Lain, S.; Verma, C.S.;...
Similarly, a single arm phase II trial (NeoPeLe) using pembrolizumab + lenvatinib showed a comparable partial pathological response of 75% (15/20 patients) and pCR of 40% (8/20 patients) [133]. In this scenario, lenvatinib is less likely to be immunomodulatory. It is also less likely to...